Literature DB >> 19958041

Migraine and functional impairment.

Jan Lewis Brandes1.   

Abstract

Migraine is a leading cause of disability worldwide; approximately half of those affected have such severe attacks that they cannot function normally in routine daily activities. Research is beginning to focus upon the burden of migraine between attacks, referred to as interictal burden. This burden encompasses worry and expectation of future attacks that consequently may be associated with limitations in social and family interactions, as well as work capacity. This review aims to increase physician awareness of the degree and scope of functional impairment associated with migraine. Physicians are in a position to assess the true impact of migraine in their patients using techniques such as open-ended questions during visits, and paper-based migraine assessment tools such as the Migraine Disability Assessment questionnaire. Eliciting such information on interictal burden may help the physician prescribe the most appropriate therapy based on their patients' degree of impairment. This article also describes the instruments most widely used for measuring migraine-related functional impairment, summarizes studies assessing the effects of migraine on indicators of health-related quality of life and presents data on how preventive migraine treatment may beneficially influence migraine-related functional impairment.

Entities:  

Mesh:

Year:  2009        PMID: 19958041     DOI: 10.2165/11530030-000000000-00000

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  43 in total

1.  Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  S D Silberstein
Journal:  Neurology       Date:  2000-09-26       Impact factor: 9.910

Review 2.  Practical use of topiramate for migraine prevention.

Authors:  Jan Lewis Brandes
Journal:  Headache       Date:  2005-04       Impact factor: 5.887

3.  Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.

Authors:  Stephen D Silberstein; Richard B Lipton; David W Dodick; Frederick G Freitag; Nabih Ramadan; Ninan Mathew; Jan L Brandes; Marcelo Bigal; Joel Saper; Steven Ascher; Donna M Jordan; Steven J Greenberg; Joseph Hulihan
Journal:  Headache       Date:  2007-02       Impact factor: 5.887

4.  Validity and reliability of the migraine-specific quality of life questionnaire (MSQ Version 2.1).

Authors:  B C Martin; D S Pathak; M I Sharfman; J U Adelman; F Taylor; W J Kwong; P Jhingran
Journal:  Headache       Date:  2000-03       Impact factor: 5.887

5.  The impact of migraine on daily activities: effect of topiramate compared with placebo.

Authors:  Stephen D Silberstein; Elizabeth Loder; Grace Forde; George Papadopoulos; Diane Fairclough; Steven Greenberg
Journal:  Curr Med Res Opin       Date:  2006-06       Impact factor: 2.580

6.  Migraine prophylaxis with divalproex.

Authors:  N T Mathew; J R Saper; S D Silberstein; L Rankin; H G Markley; S Solomon; A M Rapoport; C J Silber; R L Deaton
Journal:  Arch Neurol       Date:  1995-03

Review 7.  Measuring disability and quality of life in migraine.

Authors:  Carl G H Dahlöf
Journal:  Drugs Today (Barc)       Date:  2003       Impact factor: 2.245

8.  Migraine, physical health and psychiatric disorder: a prospective epidemiologic study in young adults.

Authors:  N Breslau; G C Davis
Journal:  J Psychiatr Res       Date:  1993 Apr-Jun       Impact factor: 4.791

9.  A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis.

Authors:  Frederick G Freitag; S D Collins; H A Carlson; J Goldstein; J Saper; S Silberstein; N Mathew; P K Winner; R Deaton; K Sommerville
Journal:  Neurology       Date:  2002-06-11       Impact factor: 9.910

10.  Attitudes and burden of disease among self-considered migraineurs--a nation-wide population-based survey in Sweden.

Authors:  M Linde; C Dahlöf
Journal:  Cephalalgia       Date:  2004-06       Impact factor: 6.292

View more
  11 in total

1.  Heuristic evaluation and usability testing of a computerized patient-reported outcomes survey for headache sufferers.

Authors:  Diane M Turner-Bowker; Renee N Saris-Baglama; Kevin J Smith; Michael A DeRosa; Christine A Paulsen; Sarah J Hogue
Journal:  Telemed J E Health       Date:  2011-01-07       Impact factor: 3.536

2.  The Impact of Migraine Disease on Work Productivity and Quality of Life Among the Adults in Riyadh, Saudi Arabia.

Authors:  Rahaf F Alkahtani; Shawg S Alrumaih; Sarah S Algezlan; Rahaf R Almutairi; Basma A Alturki; Raghad M Alanazi; Fahad A Alateeq
Journal:  Cureus       Date:  2022-08-06

Review 3.  Diclofenac potassium powder for oral solution: a review of its use in patients with acute migraine.

Authors:  Karly P Garnock-Jones
Journal:  CNS Drugs       Date:  2014-08       Impact factor: 5.749

4.  Taking the headache out of migraine.

Authors:  David Borsook; David W Dodick
Journal:  Neurol Clin Pract       Date:  2015-08

Review 5.  Why pharmacokinetic differences among oral triptans have little clinical importance: a comment.

Authors:  Anna Ferrari; Ilaria Tiraferri; Laura Neri; Emilio Sternieri
Journal:  J Headache Pain       Date:  2010-09-29       Impact factor: 7.277

6.  Quality of life and migraine disability among female migraine patients in a tertiary hospital in Malaysia.

Authors:  Munvar Miya Shaik; Norul Badriah Hassan; Huay Lin Tan; Siew Hua Gan
Journal:  Biomed Res Int       Date:  2015-01-08       Impact factor: 3.411

7.  Measuring the impact of migraine for evaluating outcomes of preventive treatments for migraine headaches.

Authors:  Sally Mannix; Anne Skalicky; Dawn C Buse; Pooja Desai; Sandhya Sapra; Brian Ortmeier; Katherine Widnell; Asha Hareendran
Journal:  Health Qual Life Outcomes       Date:  2016-10-06       Impact factor: 3.186

8.  Development and exploration of the content validity of a patient-reported outcome measure to evaluate the impact of migraine- the migraine physical function impact diary (MPFID).

Authors:  Asha Hareendran; Sally Mannix; Anne Skalicky; Martha Bayliss; Andrew Blumenfeld; Dawn C Buse; Pooja R Desai; Brian G Ortmeier; Sandhya Sapra
Journal:  Health Qual Life Outcomes       Date:  2017-11-17       Impact factor: 3.186

9.  United States Patients' Perspective of Living With Migraine: Country-Specific Results From the Global "My Migraine Voice" Survey.

Authors:  Sarah N Gibbs; Shweta Shah; Chinmay G Deshpande; Mark E Bensink; Michael S Broder; Paula K Dumas; Dawn C Buse; Pamela Vo; Todd J Schwedt
Journal:  Headache       Date:  2020-05-05       Impact factor: 5.887

Review 10.  Hypervigilance, Allostatic Load, and Migraine Prevention: Antibodies to CGRP or Receptor.

Authors:  Andrew Blumenfeld; Paul L Durham; Alexander Feoktistov; Debbie L Hay; Andrew F Russo; Ira Turner
Journal:  Neurol Ther       Date:  2021-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.